Table 2.
Clinicopathological features for intrinsic subtypes
| All cases | ER/PR+, HER2- | ER/PR+, HER2+ | HER2 type | Basal-like | Unclassified | P | |
|---|---|---|---|---|---|---|---|
|
Cases (%) |
471 (100) |
306 (65.0) |
41 (8.7) |
59 (12.5) |
37 (7.9) |
28 (5.9) |
|
|
Mean age at diagnosis (years) |
57.3 ±12.6 |
57.1 ±12.9 |
55.2 ±8.7 |
58.5 ±12.0 |
57.6 ±13.7 |
59.9 ±13.8 |
0.57 (Analysis of variance) |
|
Menopausal status at diagnosis |
0.8 (Fisher) |
||||||
| Premenopausal |
169 (35.9) |
115 (37.6) |
15 (36.6) |
18 (30.5) |
11 (29.7) |
10 (35.7) |
|
| Postmenopausal |
302 (64.1) |
191 (62.4) |
26 (63.4) |
41 (69.5) |
26 (70.3) |
18 (64.3) |
|
|
Stage |
0.1 (Cochran-Mantel-Haenszel) |
||||||
| 0 |
57 (12.1) |
41 (13.4) |
2 (4.9) |
8 (13.6) |
1 (2.7) |
5 (17.9) |
|
| I |
138 (29.3) |
97 (31.7) |
16 (39.0) |
9 (15.2) |
9 (24.3) |
7 (25.0) |
|
| IIA, IIB |
232 (49.3) |
139 (45.4) |
19 (46.3) |
34 (57.6) |
24 (64.9) |
16 (57.1) |
|
| IIIA, IIIB, IIIC |
40 (8.5) |
27 (8.8) |
4 (9.8) |
7 (11.9) |
2 (5.4) |
0 (0) |
|
| IV |
4 (0.8) |
2 (0.7) |
0 (0) |
1 (1.7) |
1 (2.7) |
0 (0) |
|
|
Histological type |
<0.01 (Fisher) |
||||||
| Papillotubular carcinoma |
94 (20.0) |
49 (16.0) |
13 (31.7) |
18 (30.5) |
7 (18.9) |
7 (28.0) |
|
| Solid-tubular carcinoma |
83 (17.6) |
36 (11.8) |
6 (14.6) |
14 (23.7) |
23 (62.2) |
4 (14.3) |
|
| Scirrhous carcinoma |
194 (41.2) |
145 (47.4) |
19 (46.4) |
18 (30.5) |
3 (8.1) |
9 (32.1) |
|
| Noninvasive carcinoma, Paget’s disease |
65 (13.8) |
49 (16.0) |
2 (4.9) |
8 (13.6) |
1 (2.7) |
5 (17.9) |
|
| Others |
35 (7.4) |
27 (8.8) |
1 (2.4) |
1 (1.7) |
3 (8.1) |
3 (10.7) |
|
|
Histological type (invasive ductal carcinoma only) |
<0.01 (Fisher) |
||||||
| Papillotubular carcinoma |
94 (25.3) |
49 (21.3) |
13 (34.2) |
18 (36.0) |
7 (21.2) |
7 (35.0) |
|
| Solid-tubular carcinoma |
83 (22.4) |
36 (15.7) |
6 (15.8) |
14 (28.0) |
23 (69.7) |
4 (20.0) |
|
| Scirrhous carcinoma |
194 (52.3) |
145 (63.0) |
19 (50.0) |
18 (36.0) |
3 (9.1) |
9 (45.0) |
|
|
Lymphatic invasion |
0.31 (Fisher) |
||||||
| Positive |
269 (57.1) |
169 (55.2) |
27 (65.9) |
31 (52.5) |
26 (70.3) |
16 (57.1) |
|
| Negative |
202 (42.9) |
137 (44.8) |
14 (34.1) |
28 (47.5) |
11 (29.7) |
12 (42.9) |
|
|
Blood vessel invasion |
0.19 (Fisher) |
||||||
| Positive |
33 (7.0) |
18 (5.9) |
4 (9.8) |
8 (13.6) |
1 (2.7) |
2 (7.1) |
|
| Negative |
438 (93.0) |
288 (94.1) |
37 (90.2) |
51 (86.4) |
36 (97.3) |
26 (92.9) |
|
|
Lymph node metastases (Level I) |
0.62 (Fisher) |
||||||
| Positive |
88 (18.7) |
59 (19.3) |
7 (17.1) |
14 (23.7) |
5 (13.5) |
3 (10.7) |
|
| Negative |
383 (81.3) |
247 (80.7) |
34 (82.9) |
45 (76.3) |
32 (86.5) |
25 (89.3) |
|
|
Lymph node metastases (Level II) |
0.97 (Fisher) |
||||||
| Positive |
30 (6.4) |
19 (6.2) |
3 (7.3) |
4 (6.8) |
2 (5.4) |
2 (7.1) |
|
| Negative |
441 (93.6) |
287 (93.8) |
38 (92.7) |
55 (93.2) |
35 (94.6) |
26 (92.9) |
|
|
Lymph node metastases (Level III) |
0.56 (Fisher) |
||||||
| Positive |
16 (3.4) |
11 (3.6) |
3 (7.3) |
1 (1.7) |
1 (2.7) |
0 (0) |
|
| Negative |
455 (96.6) |
295 (96.4) |
38 (92.7) |
58 (98.3) |
36 (97.3) |
28 (100) |
|
| |
Invasive carcinoma cases |
ER/PR+, HER2- |
ER/PR+, HER2+ |
HER2type |
Basal-like |
Unclassified |
P
|
|
Cases (%) |
406 (100%) |
257 (63.3%) |
39 (9.6%) |
51 (12.6%) |
36 (8.9%) |
23 (5.7%) |
|
|
Tumor size |
0.54 (Fisher) |
||||||
| ≤ 2.0 cm |
272 (67.0) |
179 (69.6) |
24 (61.5) |
32 (62.7) |
24 (66.7) |
13 (56.5) |
|
| >2.0 cm |
134 (33.0) |
78 (30.4) |
15 (38.5) |
19 (37.3) |
12 (33.3) |
10 (43.5) |
|
|
Histological grade (total score) |
<0.01 (Fisher) | ||||||
| Grade I |
200 (49.3) |
148 (57.6) |
21 (53.8) |
14 (27.4) |
5 (13.9) |
12 (52.2) |
|
| Grade II or III |
201 (49.5) |
106 (41.2) |
18 (46.2) |
36 (70.6) |
31 (86.1) |
10 (43.5) |
|
| Unknown | 5 (1.2) | 3 (1.2) | 0 (0) | 1 (2.0) | 0 (0) | 1 (4.3) | |